NEW ORLEANS, LA — A long-awaited trial suggests the selective cyclooxygenase-2 (COX-2) inhibitor celecoxib has similar cardiovascular safety as naproxen and ibuprofen in arthritis patients at ...
The US Food and Drug Administration (FDA) approved a labeling supplement for Pfizer’s Celebrex (celecoxib) to include the results of a 2016 trial that demonstrated similarity in safety to naproxen and ...
Two US Food and Drug Administration (FDA) panels today jointly voted by a large margin that the cardiovascular (CV) safety of celecoxib (Celebrex, Pfizer) is comparable to naproxen and ibuprofen. The ...
The addition of aspirin appears to the modify the cardiovascular and overall safety of nonsteroidal anti-inflammatory drug (NSAID) therapy, specifically the beneficial safety profile of celecoxib over ...
NEW ORLEANS (Reuters) - Pfizer Inc's Celebrex arthritis drug was shown to be at least as safe as the widely used prescription-strength versions of painkillers ibuprofen and naproxen, and does not ...
The findings, stemming from basic science research and a retrospective analysis, are particularly concerning given changes to the drug’s label clearing low-dose celecoxib against charges of an ...
High-dose celecoxib, sometimes sold under the brand name Celebrex, is effective at controlling pain and reducing narcotic use after tonsillectomy in children, according to a new study by researchers ...
Ibuprofen and celecoxib significantly decrease the need for rescue analgesic medication in the early post-discharge period, improving the quality of recovery and patient satisfaction following ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results